This meeting addressed growing demand after the final and positive UK NICE recommendations on use of RefluxStop in NHS public hospitals

Implantica AG (publ.), a MedTech company at the forefront of treatment for acid reflux with its unique device RefluxStop™, a treatment field with 1 billion sufferers, announces the successful first UK National Users Meeting bringing together 21 top anti-reflux experts in UK last week. Surgeons exchanged their real-world experiences and delved into the positive National Institute for Health and Care Excellence (NICE) recommendations on using RefluxStop in NHS hospitals, opening a vast opportunity for RefluxStop procedures in patients with poor motility, representing up to 40-50%¹ of the acid reflux (GERD/GORD) sufferers.

Mr. Ahmed Ahmed, a renowned anti-reflux surgeon at the Imperial College Healthcare NHS Trust, says, “As more and more patients ask for RefluxStop, I’m very pleased to play a part in this unique opportunity to collaborate with my colleagues to offer the latest and greatest treatment options to our GERD patients, such as RefluxStop. I’m already seeing a rapidly growing demand for RefluxStop, in line with excellent outcomes achieved in my current RefluxStop patients. The recent positive NICE recommendations now allow the use of RefluxStop in NHS hospitals, which is a testament to the UK healthcare system’s prioritization and focus on making the best treatments available to UK patients as soon as possible. On behalf of the GERD community, I would like to thank NICE and all involved stakeholders for their dedication to helping GERD patients who truly need effective treatment for this debilitating disease.”

Founder and CEO of Implantica, Dr. Peter Forsell, adds, “We sincerely thank and appreciate the world-leading healthcare policy advisory body, UK NICE, for their extensive and thorough review and announcement of the final positive recommendations for the RefluxStop™ procedure. Given how rampant GERD is in the UK, with up to 20% of the adult population struggling with the persistent discomfort and pain from the disease, the NICE recommendations for RefluxStop procedure couldn’t be more appreciated among UK specialists, addressing the huge unmet need and treatment gap, especially for the GERD patients who have poor dysmotility.¹

Dr Forsell continues, “I’m truly impressed by the great enthusiasm for RefluxStop™ from the esteemed UK surgeons and other experts. Following the highly successful UK RefluxStop™ users meeting where several UK surgeons presented their excellent outcomes and patient satisfaction results, and now with the very supportive NICE recommendations, it’s clear to me that RefluxStop™ will transform the reflux treatment landscape in the UK, and ultimately worldwide, in the coming future.”
¹Shih-Chi Ho et al., Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease. Digestive Diseases and Sciences, 2002. 47(3): 652-6

Visit www.implantica.com for further information.